Stuart J Gallagher
Overview
Explore the profile of Stuart J Gallagher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahmed F, Tseng H, Ahn A, Gunatilake D, Alavi S, Eccles M, et al.
J Invest Dermatol
. 2021 Oct;
142(5):1444-1455.e10.
PMID: 34695412
The development of resistance to treatments of melanoma is commonly associated with an upregulation of the MAPK pathway and the development of an undifferentiated state. Previous studies have suggested that...
2.
Gallagher S, Bailey T, Rawson R, Mahar A, Thompson J, Long G, et al.
Pathology
. 2021 Jun;
53(7):830-835.
PMID: 34090666
Melanoma can present with osteocartilaginous differentiation, however few reports exist on this rare subtype. We present eight cases of melanoma with osteocartilaginous differentiation to highlight its clinical, pathological and molecular...
3.
Al Emran A, Tseng H, Gunatilake D, Cook S, Ahmed F, Wang S, et al.
J Invest Dermatol
. 2021 Mar;
141(9):2238-2249.e12.
PMID: 33781756
Dysregulation of epigenetic modifiers is a frequent event in melanoma and underlies many aspects of melanoma biology, including resistance to targeted therapy and immunotherapies. Here, we report that dual targeting...
4.
Al Emran A, Gallagher S, Tiffen J, Hersey P
Br J Cancer
. 2021 Jan;
124(7):1184-1186.
PMID: 33469152
Major differences in survival of men and women from infectious diseases and cancers have been highlighted by death rates from COVID-19 infections. In cancer, attention has been focussed on differences...
5.
Al Emran A, Nsengimana J, Punnia-Moorthy G, Schmitz U, Gallagher S, Newton-Bishop J, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32731355
Background: Survival from melanoma is strongly related to patient sex, with females having a survival rate almost twice that of males. Many explanations have been proposed but have not withstood...
6.
Tiffen J, Gallagher S, Filipp F, Gunatilake D, Al Emran A, Cullinane C, et al.
J Invest Dermatol
. 2020 May;
140(12):2442-2454.e5.
PMID: 32360600
The histone methylase EZH2 is frequently dysregulated in melanoma and is associated with DNA methylation and silencing of genes involved in tumor suppression. In this study, we used chromatin immunoprecipitation...
7.
Hersey P, Tiffen J, Gallagher S
Lancet Oncol
. 2019 Dec;
20(12):1637-1638.
PMID: 31797778
No abstract available.
8.
Petit V, Raymond J, Alberti C, Pouteaux M, Gallagher S, Nguyen M, et al.
Pigment Cell Melanoma Res
. 2019 Jun;
32(6):829-841.
PMID: 31251472
RAS is frequently mutated in various tumors and known to be difficult to target. NRAS are the second most frequent mutations found in human skin melanoma after BRAF . Aside...
9.
Al Emran A, Chatterjee A, Rodger E, Tiffen J, Gallagher S, Eccles M, et al.
Trends Immunol
. 2019 Mar;
40(4):328-344.
PMID: 30853334
Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by inhibiting endogenous interferon responses...
10.
Chatterjee A, Rodger E, Ahn A, Stockwell P, Parry M, Motwani J, et al.
iScience
. 2018 Sep;
4:312-325.
PMID: 30240750
Constitutive expression of the immune checkpoint, PD-L1, inhibits anti-tumor immune responses in cancer, although the factors involved in PD-L1 regulation are poorly understood. Here we show that loss of global...